395 related articles for article (PubMed ID: 21799367)
1. Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: fluorodeoxyglucose and nonfluorodeoxyglucose tracers.
Wong KK; Arabi M; Zerizer I; Al-Nahhas A; Rubello D; Gross MD
Nucl Med Commun; 2011 Sep; 32(9):764-81. PubMed ID: 21799367
[TBL] [Abstract][Full Text] [Related]
2. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
[TBL] [Abstract][Full Text] [Related]
3. Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.
Panagiotidis E; Bomanji J
PET Clin; 2014 Jan; 9(1):43-55. PubMed ID: 25029933
[TBL] [Abstract][Full Text] [Related]
4. PET and PET/CT imaging in thyroid and adrenal diseases: an update.
Treglia G; Giovanella L; Rufini V
Hormones (Athens); 2013; 12(3):327-33. PubMed ID: 24121375
[TBL] [Abstract][Full Text] [Related]
5. Endocrine tumors: the evolving role of positron emission tomography in diagnosis and management.
Naji M; Hodolic M; El-Refai S; Khan S; Marzola MC; Rubello D; Al-Nahhas A
J Endocrinol Invest; 2010 Jan; 33(1):54-60. PubMed ID: 19820296
[TBL] [Abstract][Full Text] [Related]
6. Analysis of adrenal masses by 18F-FDG positron emission tomography scanning.
Han SJ; Kim TS; Jeon SW; Jeong SJ; Yun M; Rhee Y; Kang ES; Cha BS; Lee EJ; Lee HC; Lim SK
Int J Clin Pract; 2007 May; 61(5):802-9. PubMed ID: 17343665
[TBL] [Abstract][Full Text] [Related]
7. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
8. Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions.
Maurea S; Mainolfi C; Bazzicalupo L; Panico MR; Imparato C; Alfano B; Ziviello M; Salvatore M
AJR Am J Roentgenol; 1999 Jul; 173(1):25-9. PubMed ID: 10397094
[TBL] [Abstract][Full Text] [Related]
9. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
10. Positron Emission Tomography Computed Tomography: A Guide for the General Radiologist.
Beadsmoore C; Newman D; MacIver D; Pawaroo D
Can Assoc Radiol J; 2015 Nov; 66(4):332-47. PubMed ID: 26277234
[TBL] [Abstract][Full Text] [Related]
11. PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
Shamim SA; Kumar A; Kumar R
PET Clin; 2015 Jul; 10(3):411-21. PubMed ID: 26099675
[TBL] [Abstract][Full Text] [Related]
12. Isolated adrenal metastasis of small cell neuroendocrine carcinoma of the ovary detected with FDG-PET/CT.
Ozpacaci T; Tamam MO; Mulazimoglu M; Kamali G; Ozcan D
Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):297-8. PubMed ID: 23067537
[No Abstract] [Full Text] [Related]
13. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
14. Adrenal masses of varied etiology: anatomical and molecular imaging features on PET-CT.
Sharma P; Singh H; Dhull VS; Suman KC S; Kumar A; Bal C; Kumar R
Clin Nucl Med; 2014 Mar; 39(3):251-60. PubMed ID: 24217551
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning.
Nunes ML; Rault A; Teynie J; Valli N; Guyot M; Gaye D; Belleannee G; Tabarin A
World J Surg; 2010 Jul; 34(7):1506-10. PubMed ID: 20396886
[TBL] [Abstract][Full Text] [Related]
16. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
17. [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma.
Mann GN; Link JM; Pham P; Pickett CA; Byrd DR; Kinahan PE; Krohn KA; Mankoff DA
Ann Surg Oncol; 2006 Feb; 13(2):187-97. PubMed ID: 16418883
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI.
Yun M; Kim W; Alnafisi N; Lacorte L; Jang S; Alavi A
J Nucl Med; 2001 Dec; 42(12):1795-9. PubMed ID: 11752075
[TBL] [Abstract][Full Text] [Related]
19. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate.
Zettinig G; Mitterhauser M; Wadsak W; Becherer A; Pirich C; Vierhapper H; Niederle B; Dudczak R; Kletter K
Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1224-30. PubMed ID: 15197504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
